J. Goldman & Co LP Buys New Shares in Pacira BioSciences, Inc. $PCRX

Posted by George Bondi on Aug 27th, 2026

J. Goldman & Co LP purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,078 shares of the company’s stock, valued at approximately $560,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its position in shares of Pacira BioSciences by 0.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company’s stock valued at $55,751,000 after purchasing an additional 11,831 shares during the last quarter. Balyasny Asset Management L.P. boosted its stake in Pacira BioSciences by 36.1% in the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock worth $50,925,000 after buying an additional 565,288 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after acquiring an additional 367,869 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Pacira BioSciences by 7.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 676,352 shares of the company’s stock valued at $17,504,000 after acquiring an additional 49,079 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of Pacira BioSciences by 7.9% during the third quarter. Invesco Ltd. now owns 517,424 shares of the company’s stock worth $13,334,000 after acquiring an additional 38,025 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 16th. Needham & Company LLC increased their target price on shares of Pacira BioSciences from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Royal Bank Of Canada lifted their target price on shares of Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a research note on Monday, August 17th. Finally, Truist Financial began coverage on shares of Pacira BioSciences in a research note on Monday, August 17th. They issued a “buy” rating and a $30.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $30.20.

Check Out Our Latest Report on Pacira BioSciences

Pacira BioSciences Price Performance

PCRX opened at $25.90 on Thursday. The stock’s 50 day simple moving average is $25.05 and its 200 day simple moving average is $23.78. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.04 and a quick ratio of 3.94. Pacira BioSciences, Inc. has a 1 year low of $18.80 and a 1 year high of $27.66. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of 74.00 and a beta of 0.27.

Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The business had revenue of $192.40 million for the quarter, compared to analysts’ expectations of $191.06 million. During the same period in the previous year, the firm earned $0.74 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, analysts predict that Pacira BioSciences, Inc. will post 1.98 earnings per share for the current year.

Insider Activity at Pacira BioSciences

In related news, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the sale, the senior vice president directly owned 62,284 shares in the company, valued at $1,463,674. This represents a 8.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the sale, the insider directly owned 216,384 shares of the company’s stock, valued at $5,026,600.32. The trade was a 1.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by company insiders.

Pacira BioSciences Profile

(Free Report)

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.